Education
About Us
Working with TipRanks
Follow Us
Repligen Corp (RGEN)
NASDAQ:RGEN
RGEN Analyst Ratings
Strong Buy
11 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
RGEN Stock 12 Month Forecast
Average Price Target
$181.67
▲(47.88%Upside)
| Highest Price Target$220.00 | Average Price Target$181.67 | Lowest Price Target$130.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$122
Hold
-0.69%
Downside
Reiterated
07/31/25
Wells Fargo
$180→$175
Buy
42.45%
Upside
Reiterated
07/30/25
KeyBanc
$220
Buy
79.08%
Upside
Reiterated
07/30/25
Evercore ISI
$130
Hold
5.82%
Upside
Reiterated
07/30/25
Stifel Nicolaus
$207
Buy
68.50%
Upside
Reiterated
07/30/25
Craig-Hallum
$204
Buy
66.06%
Upside
Reiterated
07/30/25
Leerink Partners
$200
Buy
62.80%
Upside
Reiterated
07/30/25
Barclays
$150
Buy
22.10%
Upside
Reiterated
07/30/25
RBC Capital
$193→$204
Buy
66.06%
Upside
Reiterated
07/30/25
TD Cowen
$200
Buy
62.80%
Upside
Reiterated
07/29/25
William Blair
―
Buy
―
Reiterated
07/29/25
Repligen's Strong Q2 Performance and Growth Prospects Justify Buy RatingWe will update our model and estimates after the conference call. What Happened Repligen’s second-quarter results came in ahead on the top line and the company raised the low end of its non-COVID organic growth guidance. Revenue: $182.4 million beat our $177.1 million estimate and consensus of $175.2 million (non-COVID organic growth was 17% versus our roughly 14% estimate). Gross margin: 51.1% (WB: 52.0%; $32.2 million (WB: $33.7 million; Street: $32.1 million). Adjusted EPS: $0.37 (WB: $0.41; Updated full-year guidance calls for revenue of $715 million to $735 million (up from $695 million to $720 million), non- COVID organic growth of 12.5% to 15.5% (up from 11.5% to 15.5%), adjusted EBITDA margin of 19.5% to 20.5% (unchanged), and adjusted EPS of $1.65 to $1.75 (up from $1.63 to $1.72).
Canaccord Genuity
$150
Hold
22.10%
Upside
Reiterated
07/29/25
Stephens
$160
Buy
30.24%
Upside
Initiated
07/21/25
H.C. Wainwright
$180
Buy
46.52%
Upside
Reiterated
05/05/25
Benchmark Co.
―
Hold
―
Reiterated
04/30/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$122
Hold
-0.69%
Downside
Reiterated
07/31/25
Wells Fargo
$180→$175
Buy
42.45%
Upside
Reiterated
07/30/25
KeyBanc
$220
Buy
79.08%
Upside
Reiterated
07/30/25
Evercore ISI
$130
Hold
5.82%
Upside
Reiterated
07/30/25
Stifel Nicolaus
$207
Buy
68.50%
Upside
Reiterated
07/30/25
Craig-Hallum
$204
Buy
66.06%
Upside
Reiterated
07/30/25
Leerink Partners
$200
Buy
62.80%
Upside
Reiterated
07/30/25
Barclays
$150
Buy
22.10%
Upside
Reiterated
07/30/25
RBC Capital
$193→$204
Buy
66.06%
Upside
Reiterated
07/30/25
TD Cowen
$200
Buy
62.80%
Upside
Reiterated
07/29/25
William Blair
―
Buy
―
Reiterated
07/29/25
Repligen's Strong Q2 Performance and Growth Prospects Justify Buy RatingWe will update our model and estimates after the conference call. What Happened Repligen’s second-quarter results came in ahead on the top line and the company raised the low end of its non-COVID organic growth guidance. Revenue: $182.4 million beat our $177.1 million estimate and consensus of $175.2 million (non-COVID organic growth was 17% versus our roughly 14% estimate). Gross margin: 51.1% (WB: 52.0%; $32.2 million (WB: $33.7 million; Street: $32.1 million). Adjusted EPS: $0.37 (WB: $0.41; Updated full-year guidance calls for revenue of $715 million to $735 million (up from $695 million to $720 million), non- COVID organic growth of 12.5% to 15.5% (up from 11.5% to 15.5%), adjusted EBITDA margin of 19.5% to 20.5% (unchanged), and adjusted EPS of $1.65 to $1.75 (up from $1.63 to $1.72).
Canaccord Genuity
$150
Hold
22.10%
Upside
Reiterated
07/29/25
Stephens
$160
Buy
30.24%
Upside
Initiated
07/21/25
H.C. Wainwright
$180
Buy
46.52%
Upside
Reiterated
05/05/25
Benchmark Co.
―
Hold
―
Reiterated
04/30/25
Best Analysts Covering Repligen
1 Month
xxx
Success Rate
11/19 ratings generated profit
Average Return
+2.45%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 57.89% of your transactions generating a profit, with an average return of +2.45% per trade.
3 Months
xxx
Success Rate
7/11 ratings generated profit
Average Return
+0.55%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +0.55% per trade.
1 Year
Success Rate
11/23 ratings generated profit
Average Return
+15.79%
reiterated a buy rating 2 days ago
Copying Daniel Arias's trades and holding each position for 1 Year would result in 47.83% of your transactions generating a profit, with an average return of +15.79% per trade.
2 Years
xxx
Success Rate
7/23 ratings generated profit
Average Return
+19.13%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 30.43% of your transactions generating a profit, with an average return of +19.13% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
RGEN Analyst Recommendation Trends
Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
0
3
3
5
9
Buy
23
30
17
12
9
Hold
5
10
7
5
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
28
43
27
22
26
Each month's total comprises the sum of three months' worth of ratings.
RGEN Financial Forecast
RGEN Stock Forecast FAQ
What is RGEN’s average 12-month price target, according to analysts?
Based on analyst ratings, Repligen Corp’s 12-month average price target is 181.67.
What is RGEN’s upside potential, based on the analysts’ average price target?
Repligen Corp has 47.88% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is RGEN a Buy, Sell or Hold?
Repligen Corp has a consensus rating of Strong Buy which is based on 11 buy ratings, 2 hold ratings and 0 sell ratings.
What is Repligen Corp’s price target?
The average price target for Repligen Corp is 181.67. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $220.00 ,the lowest forecast is $130.00. The average price target represents 47.88% Increase from the current price of $122.85.
The highest analyst price target is $220.00 ,the lowest forecast is $130.00. The average price target represents 47.88% Increase from the current price of $122.85.
What do analysts say about Repligen Corp?
Repligen Corp’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
How can I buy shares of RGEN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.